SCHEMBL2611287

SCHEMBL2611287

Cc1ncc(-c2nc3cc(C(=O)NO)ccc3c(=O)n2Cc2ccc(C(F)(F)F)cc2)n1C

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 17/20 0.49
HDAC6 Q9UBN7 16/20 0.49
HDAC8 Q9BY41 11/20 0.49
HDAC11 Q96DB2 6/20 0.49
HDAC2 Q92769 5/20 0.49
HDAC3 O15379 4/20 0.49
HDAC9 Q9UKV0 3/20 0.49
HDAC4 P56524 2/20 0.49
HDAC7 Q8WUI4 2/20 0.49
HDAC10 Q969S8 2/20 0.49
HDAC5 Q9UQL6 2/20 0.49
NCOR2 Q9Y618 1/20 0.41
KDM1A O60341 1/20 0.39
MMP13 P45452 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2611324 0.85 HDAC6 (0.54) HDAC1HDAC6HDAC8HDAC11HDAC2
SCHEMBL2611204 0.82 HDAC6 (0.47) HDAC1HDAC6HDAC8HDAC11HDAC2
SCHEMBL2611263 0.82 HDAC6 (0.56) HDAC1HDAC6HDAC8HDAC11HDAC2
SCHEMBL2619241 0.81 HDAC6 (0.55) HDAC1HDAC6HDAC8HDAC11HDAC2
SCHEMBL2611390 0.80 HDAC6 (0.47) HDAC1HDAC6HDAC8HDAC11HDAC2
SCHEMBL2619242 0.80 HDAC6 (0.51) HDAC1HDAC6HDAC8HDAC11HDAC2
SCHEMBL2619415 0.79 HDAC6 (0.51) HDAC1HDAC6HDAC8HDAC11HDAC2
SCHEMBL4550029 0.78 HDAC6 (0.46) HDAC1HDAC6HDAC8HDAC11HDAC2
SCHEMBL2611220 0.78 HDAC6 (0.51) HDAC1HDAC6HDAC8HDAC11HDAC2
SCHEMBL2611245 0.78 HDAC6 (0.49) HDAC1HDAC6HDAC8HDAC11HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-11 US disclosed
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-11 US disclosed
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2016-02-11 US disclosed
US-8765773-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-8765773-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-8765773-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-07-01 US disclosed
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094997-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 HDAC1 2/4885HDAC6 1/4885HDAC8 14/4885
US-20160039789-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC5 HDAC1 2/4885HDAC6 1/4885HDAC8 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.